DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are ...

The market reacted favourably with 2seventy bio’s share price increasing by 76% since the news announcement. . Adjusted ... treatment landscape for NDMM [newly diagnosed multiple myeloma ...

Sanofi’s Sarclisa has received approval in more than 50 nations and regions. Credit: LCV/Shutterstock. Sanofi’s Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and ...

Adding daratumumab to VRd therapy significantly improves survival outcomes in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma (NDMM), supporting its use as a new standard ...

The multicenter, randomized, open-label AURIGA study (ClinicalTrials.gov Identifier: NCT03901963) enrolled patients with NDMM and an age of 18 to 79 years who had not received anti-CD38 therapy.

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...